Thanks for asking. The calculations in #msg-92234861 refer to ENTA’s target price following ABBV’s HCV product launch in 1H15, assuming no delay in FDA and EU approvals (and also no delay for GILD’s all-oral approvals in genotype-1 patients). Readers can use whatever discount rate and risk adjustment they want to derive an NPV figure.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.